242 related articles for article (PubMed ID: 37787146)
41. Differences Between Plasma and Cerebrospinal Fluid Glial Fibrillary Acidic Protein Levels Across the Alzheimer Disease Continuum.
Benedet AL; Milà-Alomà M; Vrillon A; Ashton NJ; Pascoal TA; Lussier F; Karikari TK; Hourregue C; Cognat E; Dumurgier J; Stevenson J; Rahmouni N; Pallen V; Poltronetti NM; Salvadó G; Shekari M; Operto G; Gispert JD; Minguillon C; Fauria K; Kollmorgen G; Suridjan I; Zimmer ER; Zetterberg H; Molinuevo JL; Paquet C; Rosa-Neto P; Blennow K; Suárez-Calvet M;
JAMA Neurol; 2021 Dec; 78(12):1471-1483. PubMed ID: 34661615
[TBL] [Abstract][Full Text] [Related]
42. Association of plasma biomarkers of Alzheimer's disease and related disorders with cognition and cognitive decline: The MYHAT population-based study.
Zhang Y; Ferreira PCL; Jacobsen E; Bellaver B; Pascoal TA; Snitz BE; Chang CH; Villemagne VL; Ganguli M; Karikari TK
Alzheimers Dement; 2024 Jun; 20(6):4199-4211. PubMed ID: 38753951
[TBL] [Abstract][Full Text] [Related]
43. Spatial Extent of Amyloid-β Levels and Associations With Tau-PET and Cognition.
Ozlen H; Pichet Binette A; Köbe T; Meyer PF; Gonneaud J; St-Onge F; Provost K; Soucy JP; Rosa-Neto P; Breitner J; Poirier J; Villeneuve S;
JAMA Neurol; 2022 Oct; 79(10):1025-1035. PubMed ID: 35994280
[TBL] [Abstract][Full Text] [Related]
44. Plasma VEGFA and PGF impact longitudinal tau and cognition in preclinical Alzheimer's disease.
Yang HS; Yau WW; Carlyle BC; Trombetta BA; Zhang C; Shirzadi Z; Schultz AP; Pruzin JJ; Fitzpatrick CD; Kirn DR; Rabin JS; Buckley RF; Hohman TJ; Rentz DM; Tanzi RE; Johnson KA; Sperling RA; Arnold SE; Chhatwal JP
Brain; 2024 Jun; 147(6):2158-2168. PubMed ID: 38315899
[TBL] [Abstract][Full Text] [Related]
45. Accuracy of Tau Positron Emission Tomography as a Prognostic Marker in Preclinical and Prodromal Alzheimer Disease: A Head-to-Head Comparison Against Amyloid Positron Emission Tomography and Magnetic Resonance Imaging.
Ossenkoppele R; Smith R; Mattsson-Carlgren N; Groot C; Leuzy A; Strandberg O; Palmqvist S; Olsson T; Jögi J; Stormrud E; Cho H; Ryu YH; Choi JY; Boxer AL; Gorno-Tempini ML; Miller BL; Soleimani-Meigooni D; Iaccarino L; La Joie R; Baker S; Borroni E; Klein G; Pontecorvo MJ; Devous MD; Jagust WJ; Lyoo CH; Rabinovici GD; Hansson O
JAMA Neurol; 2021 Aug; 78(8):961-971. PubMed ID: 34180956
[TBL] [Abstract][Full Text] [Related]
46. Plasma biomarkers for diagnosis of Alzheimer's disease and prediction of cognitive decline in individuals with mild cognitive impairment.
Kivisäkk P; Carlyle BC; Sweeney T; Trombetta BA; LaCasse K; El-Mufti L; Tuncali I; Chibnik LB; Das S; Scherzer CR; Johnson KA; Dickerson BC; Gomez-Isla T; Blacker D; Oakley DH; Frosch MP; Hyman BT; Aghvanyan A; Bathala P; Campbell C; Sigal G; Stengelin M; Arnold SE
Front Neurol; 2023; 14():1069411. PubMed ID: 36937522
[TBL] [Abstract][Full Text] [Related]
47. Association of short-term cognitive decline and MCI-to-AD dementia conversion with CSF, MRI, amyloid- and
Ottoy J; Niemantsverdriet E; Verhaeghe J; De Roeck E; Struyfs H; Somers C; Wyffels L; Ceyssens S; Van Mossevelde S; Van den Bossche T; Van Broeckhoven C; Ribbens A; Bjerke M; Stroobants S; Engelborghs S; Staelens S
Neuroimage Clin; 2019; 22():101771. PubMed ID: 30927601
[TBL] [Abstract][Full Text] [Related]
48. Biomarker-Based Prediction of Longitudinal Tau Positron Emission Tomography in Alzheimer Disease.
Leuzy A; Smith R; Cullen NC; Strandberg O; Vogel JW; Binette AP; Borroni E; Janelidze S; Ohlsson T; Jögi J; Ossenkoppele R; Palmqvist S; Mattsson-Carlgren N; Klein G; Stomrud E; Hansson O
JAMA Neurol; 2022 Feb; 79(2):149-158. PubMed ID: 34928318
[TBL] [Abstract][Full Text] [Related]
49. Longitudinal changes in Alzheimer's-related plasma biomarkers and brain amyloid.
Bilgel M; An Y; Walker KA; Moghekar AR; Ashton NJ; Kac PR; Karikari TK; Blennow K; Zetterberg H; Jedynak BM; Thambisetty M; Ferrucci L; Resnick SM
Alzheimers Dement; 2023 Oct; 19(10):4335-4345. PubMed ID: 37216632
[TBL] [Abstract][Full Text] [Related]
50. Amyloid-beta modulates the association between neurofilament light chain and brain atrophy in Alzheimer's disease.
Kang MS; Aliaga AA; Shin M; Mathotaarachchi S; Benedet AL; Pascoal TA; Therriault J; Chamoun M; Savard M; Devenyi GA; Mathieu A; Chakravarty MM; Sandelius Å; Blennow K; Zetterberg H; Soucy JP; Cuello AC; Massarweh G; Gauthier S; Rosa-Neto P;
Mol Psychiatry; 2021 Oct; 26(10):5989-6001. PubMed ID: 32591633
[TBL] [Abstract][Full Text] [Related]
51. Arterial hypertension and β-amyloid accumulation have spatially overlapping effects on posterior white matter hyperintensity volume: a cross-sectional study.
Bernal J; Schreiber S; Menze I; Ostendorf A; Pfister M; Geisendörfer J; Nemali A; Maass A; Yakupov R; Peters O; Preis L; Schneider L; Herrera AL; Priller J; Spruth EJ; Altenstein S; Schneider A; Fliessbach K; Wiltfang J; Schott BH; Rostamzadeh A; Glanz W; Buerger K; Janowitz D; Ewers M; Perneczky R; Rauchmann BS; Teipel S; Kilimann I; Laske C; Munk MH; Spottke A; Roy N; Dobisch L; Dechent P; Scheffler K; Hetzer S; Wolfsgruber S; Kleineidam L; Schmid M; Berger M; Jessen F; Wirth M; Düzel E; Ziegler G
Alzheimers Res Ther; 2023 May; 15(1):97. PubMed ID: 37226207
[TBL] [Abstract][Full Text] [Related]
52. Serum markers glial fibrillary acidic protein and neurofilament light for prognosis and monitoring in cognitively normal older people: a prospective memory clinic-based cohort study.
Verberk IMW; Laarhuis MB; van den Bosch KA; Ebenau JL; van Leeuwenstijn M; Prins ND; Scheltens P; Teunissen CE; van der Flier WM
Lancet Healthy Longev; 2021 Feb; 2(2):e87-e95. PubMed ID: 36098162
[TBL] [Abstract][Full Text] [Related]
53. Plasma glial fibrillary acidic protein in autosomal dominant Alzheimer's disease: Associations with Aβ-PET, neurodegeneration, and cognition.
Chatterjee P; Vermunt L; Gordon BA; Pedrini S; Boonkamp L; Armstrong NJ; Xiong C; Singh AK; Li Y; Sohrabi HR; Taddei K; Molloy M; Benzinger TLS; Morris JC; Karch C; Berman S; Chhatwal J; Cruchaga C; Graff-Radford NR; Day GS; Farlow M; Fox N; Goate A; Hassenstab J; Lee JH; Levin J; McDade E; Mori H; Perrin R; Sanchez-Valle R; Schofield PR; Levey A; Jucker M; Masters CL; Fagan AM; Bateman RJ; Martins RN; Teunissen C;
Alzheimers Dement; 2023 Jul; 19(7):2790-2804. PubMed ID: 36576155
[TBL] [Abstract][Full Text] [Related]
54. Clinical Significance of the Plasma Biomarker Panels in Amyloid-Negative and Tau PET-Positive Amnestic Patients: Comparisons with Alzheimer's Disease and Unimpaired Cognitive Controls.
Chang HI; Huang KL; Huang CG; Huang CW; Huang SH; Lin KJ; Chang CC
Int J Mol Sci; 2024 May; 25(11):. PubMed ID: 38891795
[TBL] [Abstract][Full Text] [Related]
55. Longitudinal β-Amyloid Deposition and Hippocampal Volume in Preclinical Alzheimer Disease and Suspected Non-Alzheimer Disease Pathophysiology.
Gordon BA; Blazey T; Su Y; Fagan AM; Holtzman DM; Morris JC; Benzinger TL
JAMA Neurol; 2016 Oct; 73(10):1192-1200. PubMed ID: 27548756
[TBL] [Abstract][Full Text] [Related]
56. Phospho-tau with subthreshold tau-PET predicts increased tau accumulation rates in amyloid-positive individuals.
Groot C; Smith R; Stomrud E; Binette AP; Leuzy A; Wuestefeld A; Wisse LEM; Palmqvist S; Mattsson-Carlgren N; Janelidze S; Strandberg O; Ossenkoppele R; Hansson O
Brain; 2023 Apr; 146(4):1580-1591. PubMed ID: 36084009
[TBL] [Abstract][Full Text] [Related]
57. Relationships between flortaucipir PET tau binding and amyloid burden, clinical diagnosis, age and cognition.
Pontecorvo MJ; Devous MD; Navitsky M; Lu M; Salloway S; Schaerf FW; Jennings D; Arora AK; McGeehan A; Lim NC; Xiong H; Joshi AD; Siderowf A; Mintun MA;
Brain; 2017 Mar; 140(3):748-763. PubMed ID: 28077397
[TBL] [Abstract][Full Text] [Related]
58. Head-to-head comparison of plasma p-tau181, p-tau231 and glial fibrillary acidic protein in clinically unimpaired elderly with three levels of APOE4-related risk for Alzheimer's disease.
Snellman A; Ekblad LL; Ashton NJ; Karikari TK; Lantero-Rodriguez J; Pietilä E; Koivumäki M; Helin S; Karrasch M; Zetterberg H; Blennow K; Rinne JO
Neurobiol Dis; 2023 Jul; 183():106175. PubMed ID: 37268240
[TBL] [Abstract][Full Text] [Related]
59. Plasma and CSF biomarkers for the diagnosis of Alzheimer's disease in adults with Down syndrome: a cross-sectional study.
Fortea J; Carmona-Iragui M; Benejam B; Fernández S; Videla L; Barroeta I; Alcolea D; Pegueroles J; Muñoz L; Belbin O; de Leon MJ; Maceski AM; Hirtz C; Clarimón J; Videla S; Delaby C; Lehmann S; Blesa R; Lleó A
Lancet Neurol; 2018 Oct; 17(10):860-869. PubMed ID: 30172624
[TBL] [Abstract][Full Text] [Related]
60. Relationship between topological efficiency of white matter structural connectome and plasma biomarkers across the Alzheimer's disease continuum.
Zhang M; Chen H; Huang W; Guo T; Ma G; Han Y; Shu N
Hum Brain Mapp; 2024 Jan; 45(1):e26566. PubMed ID: 38224535
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
